Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision.
Melanoma is the most common oral malignancy in dogs. This retrospective study evaluated adjuvant carboplatin chemotherapy (with or without radiation therapy) in 17 dogs with malignant oral melanoma following surgical resection. The median dosage and number of doses of carboplatin administered to the 17 dogs was 300 mg m(-2) (range, 150-300 mg m(-2)) and 4 (range, 2-11), respectively. The overall median progression-free survival for all dogs was 259 days [95% confidence interval (CI95), 119-399 days]. The first progression-free survival event was local recurrence in seven dogs (41%) and metastases in seven dogs (41%). The median overall survival for all dogs was 440 days (CI95, 247-633 days). The tumour was the cause of death in 10 dogs (59%). On the basis of this study, systemic therapy with carboplatin may be an appropriate adjunct to local treatment for canine malignant melanoma, although future prospective controlled studies are needed to compare treatment modalities for this aggressive neoplasia.
Koret School of Veterinary Medicine, Hebrew University, Rehovot, Israel.
G
G
Dank
K M
KM
Rassnick
Y
Y
Sokolovsky
L D
LD
Garrett
G S
GS
Post
B E
BE
Kitchell
R K
RK
Sellon
M
M
Kleiter
N
N
Northrup
G
G
Segev
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000601:surgery; D004285:Dogs; D005260:Female; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000601:surgery / Q000662:veterinary*; D009062:Mouth Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000662:veterinary*; D012189:Retrospective Studies; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D016190:Carboplatin